These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29851667)

  • 1. Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    Loureiro RV; Costa MN; Germano I; Calinas F
    AIDS; 2018 Jun; 32(10):1387-1388. PubMed ID: 29851667
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
    J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological properties and clinical findings of new drugs for the treatment of HIV-1, FTC/TAF 200/10 and 200/25 mg (Descovy
    Nakamoto H; Yamada H; Watanabe Y
    Nihon Yakurigaku Zasshi; 2017; 150(5):251-260. PubMed ID: 29118289
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
    Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE
    Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine.
    Fulco PP; Higginson RT
    Am J Health Syst Pharm; 2018 May; 75(10):594-595. PubMed ID: 29748295
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
    Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
    AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient.
    Béguelin C; Vazquez M; Moradpour D; Sahli R; Suter F; Rauch A; Wandeler G
    AIDS; 2016 Jan; 30(3):530-2. PubMed ID: 26760236
    [No Abstract]   [Full Text] [Related]  

  • 11. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
    Mikulska M; Taramasso L; Giacobbe DR; Caligiuri P; Bruzzone B; Di Biagio A; Viscoli C
    J Med Virol; 2012 Sep; 84(9):1340-3. PubMed ID: 22825811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis.
    Jewsbury S; Ward C
    Int J STD AIDS; 2020 Jan; 31(1):85-87. PubMed ID: 31801029
    [No Abstract]   [Full Text] [Related]  

  • 14. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Special considerations and treatment of patients with HBV-HIV coinfection.
    Dieterich DT
    Antivir Ther; 2007; 12 Suppl 3():H43-51. PubMed ID: 18284182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
    Béguelin C; Friolet N; Moradpour D; Sahli R; Suter-Riniker F; Lüthi A; Cavassini M; Günthard HF; Battegay M; Bernasconi E; Schmid P; Calmy A; Atkinson A; Rauch A; Wandeler G;
    Clin Infect Dis; 2017 May; 64(9):1275-1278. PubMed ID: 28199492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.
    Santos SA; Uriel AJ; Park JS; Lucas J; Carriero D; Jaffe D; Dieterich DT
    Eur J Gastroenterol Hepatol; 2006 Dec; 18(12):1247-53. PubMed ID: 17099372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
    Citerne Q; Boyer L; Moreau E; Garon J; Gillet P; Petitpain N
    AIDS; 2019 Jul; 33(9):1535-1536. PubMed ID: 31259768
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.
    de Vries-Sluijs TE; Reijnders JG; Hansen BE; Zaaijer HL; Prins JM; Pas SD; Schutten M; Hoepelman AI; Richter C; Mulder JW; de Man RA; Janssen HL; van der Ende ME
    Gastroenterology; 2010 Dec; 139(6):1934-41. PubMed ID: 20801123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
    Lortholary O; Roussillon C; Boucherie C; Padoin C; Chaix ML; Breton G; Rami A; Veziris N; Patey O; Caumes E; May T; Molina JM; Robert J; Tod M; Fagard C; Chêne G;
    J Antimicrob Chemother; 2016 Mar; 71(3):783-93. PubMed ID: 26679250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.